Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1602.30
₹112.20(7.01%)
At close: 4:00 PM EDT
₹1602.30
₹112.20(7.01%)
Day’s Range― - ―
52-Week Range₹822.85 - ₹1,870.00
Previous CloseN/A
Volume7.99M
Average Volume (3M)107.31K
Market Cap
₹980.48B
Enterprise Value₹560.82K
Total Cash (Recent Filing)₹1.14B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)89.0
Beta0.96
Next Earnings
Oct 22, 2026EPS Estimate
5.58Next Dividend Ex-DateN/A
Dividend Yield0.11%
Share Statistics
EPS (TTM)20.25
Shares Outstanding540,312,200
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)10.11
Price to Sales (P/S)7.86
P/FCF Ratio137.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,700.00Price Target Upside6.10% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)24.69
Revenue Forecast (FY)₹83.34B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryThe return to revenue growth indicates demand resilience across Laurus Labs’ API, finished-dose and CDMO activities. Although the growth path has been uneven, renewed expansion can support better capacity utilization and operating leverage if sustained.
Profitability ReboundThe sharp improvement in net margin demonstrates meaningful earnings recovery from the FY2024–FY2025 trough. A solid EBITDA margin also shows that the core manufacturing platform retains operating strength, even though profitability has not returned to earlier peak levels.
Improving LeverageLower leverage and a rising equity base improve financial resilience and reduce balance-sheet pressure as the company invests in manufacturing scale. This gives Laurus Labs greater flexibility to fund growth while limiting sensitivity to future earnings volatility.
Bears Say
Weak Free Cash FlowPersistently weak free cash flow suggests that capital expenditure and working-capital needs are absorbing a large share of earnings. This limits internal funding capacity, reduces financial flexibility and could restrain growth or debt reduction if the pattern continues.
Gross Margin CompressionThe sustained decline in gross margin points to potential input-cost pressure, pricing competition or an unfavorable product mix. Even with EBITDA recovery, lower gross profitability can limit earnings durability and weaken the benefit of future revenue growth.
Uneven Growth ProfileThe inconsistent revenue trajectory indicates that demand, product mix or customer programs may remain volatile across APIs, formulations and CDMO services. This makes utilization and earnings planning less predictable and raises execution risk during expansion.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹822.85 and its highest was ₹1870.00 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹980.48B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Oct 22, 2026 which is in 58 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jul 24, 2026. The company reported ₹6.8 earnings per share for the quarter, beating the consensus estimate of ₹4.912 by ₹1.888.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Semiannually dividend of ₹1.2 which represents an annual dividend yield of 0.11%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 5.58.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 540,312,200 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹6.8 in its last earnings report, beating expectations of ₹4.912. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,700.00
▲(6.10% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―







